Epirium Bio Inc. (Epirium), a clinical stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced the upcoming presentation of two scientific posters ...

In a recent study published in Science Advances, researchers led by Prof. Li Xinjian from the Institute of Biophysics of the ...

Obesity is a major global health issue, increasing the risk of heart disease, diabetes, and high blood pressure. Despite many ...

Researchers found that apple peels from local and commercial varieties are rich in phenolic compounds with antioxidant and ...

Researchers at Kumamoto University have successfully executed a practical trial of a new genome-editing technique that allows ...

All products featured on Allure are independently selected by Allure editors. However, when you buy something through our ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...

Cancer cells have an insatiable appetite for energy as they multiply more rapidly than normal cells. Greedy cancer cells hijack various cellular functions to find and exploit energy and other ...

So as way of background, EZH2 is an epigenetic enzyme that's overexpressed in castrate-resistant prostate cancer, and it's ...

Cancer cells have an insatiable appetite for energy as they multiply more rapidly than normal cells. Greedy cancer cells ...

Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease.